J. Scott Wolchko - Jan 20, 2022 Form 4/A - Amendment Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jan 20, 2022
Transactions value $
$81,000
Form type
4/A - Amendment
Date filed
2/4/2022, 04:59 PM
Date Of Original Report
Jan 24, 2022
Previous filing
Jan 13, 2022
Next filing
Jan 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $81K +30K +6.95% $2.70 462K Jan 20, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -30K -25.81% $0.00 86.2K Jan 20, 2022 Common Stock 30K $2.70 Direct F1, F2, F3, F4
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -10K -11.59% $0.00 76.2K Jan 21, 2022 Common Stock 10K $2.70 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.
F2 Corrected option price.
F3 This stock option is fully vested.
F4 Corrected ending balance of this option which includes 36,800 shares that are vested and outstanding pursuant to a second option grant issued on January 12, 2016.

Remarks:

This amended Form 4 corrects the option exercise price and ending balance of the Reporting Person's stock options that were granted on January 12, 2016 at $2.70 per share. The other transactions that were reported on the Form 4 filed on January 24, 2022 were correct and such line items are not required to be restated in this amendment.